

LifeLabs GENETICS®

Panorama™
Non-Invasive Prenatal Test (NIPT)

Used for over 3 million pregnancies across 90 countries, Panorama™ is a highly accurate prenatal screening test that screens for common chromosomal conditions that can affect baby's health.

Certified Lab

natera™ | Panorama™ Next-generation NIPT

What is Panorama™ Non-Invasive Prenatal Testing (NIPT)?

Panorama™ NIPT is a highly accurate prenatal screening test that analyzes cell-free DNA (cfDNA) to estimate the risk of fetal chromosomal conditions that affect fetal development.



cfDNA is the non-encapsulated DNA present in mother's blood during pregnancy.

cfDNA that is analyzed is derived from:

- **PLACENTAL DNA - That makes its way to the maternal circulation**
- **MATERNAL DNA - Adipocytes, white blood cells**

- Panorama™ is the **only NIPT** that uses unique SNP (Single Nucleotide Polymorphism) technology to distinguish between maternal and fetal DNA, resulting in fewer false positives and false negatives compared to traditional serum screening or counting based NIPTs.
- Panorama™ NIPT is available through a simple, convenient blood draw for pregnant women **at LifeLabs and partnered locations.**
- Panorama™ can be performed as early as nine weeks gestation. Most results will be returned to the doctor within **7-10** calendar days.

Panorama™ screens for:

	Singleton	Identical twins	Fraternal twins	Singleton egg donor and gestational carrier
Trisomies 21, 18, 13	✓	✓	✓	✓
Monosomy X (Turner syndrome)	✓	✓		
Sex chromosome trisomies	✓	✓		
22q11.2 deletion syndrome (22q11.2DS), optional	✓	✓		
Additional microdeletion syndromes, optional	✓			
Fetal sex, optional	✓	✓	✓	✓
Individual fetal sex, optional			✓	
Zygosity (degree of genetic similarity in each pair)		✓	✓	
Individual fetal fraction			✓	
Triploidy (extra set of chromosomes)	✓			

Scan here to learn more about **Panorama™**

Available through Panorama™ only![7-10]

Panorama™ is the only SNP-based NIPT in the market

The Single Nucleotide Polymorphism (SNP) technology used by Panorama™ NIPT distinguishes between the maternal and fetal (placental) DNA.

SNPs

SNPs are 1% of our DNA that make us different from one another.

Panorama™ analyzes 13,392 SNPs on the chromosomes of interest to check if the fetal DNA is present in the usual quantities or if there are more or less copies than expected.

Fewer false positives and false negatives, resulting in more accurate results



Counting NIPTs

Other NIPTs look at DNA in aggregate making them more susceptible to false positives.

More susceptible to false positives



Higher positive predictive value (PPV) = Less anxiety for patients

Traditional Screening

PPV: 3-4%

Maternal serum screening would require **265** women to undergo invasive testing to discover **9** true positives.[27]

Non-Invasive Prenatal Testing (NIPT)

PPV: 95%*

With NIPT, **10** women will undergo invasive testing to discover **9** true positives.[28,29]

*Specific to Trisomy 21

LifeLabsGenetics.com/Panorama

LifeLabs GENETICS®

Why choose Panorama™ NIPT?

TESTS
3 MILLION+
performed across 90 countries

PATIENTS
1.3 MILLION+
studied

PUBLICATIONS
25+



Patient support every step of the way

Services included with Panorama™ NIPT:

Patient Education

Patient-friendly materials available on our website and patient service centres in English and French.

Convenient Sample Collection and Testing Within Canada

Panorama™ NIPT samples can be collected at any LifeLabs patient service centre or national affiliates and testing is performed within Canada.

Genetic Counselling Support

Certified Canadian genetic counsellors are available to healthcare providers and patients to answer any questions about the test or results at **Ask.Genetics@LifeLabs.com** or **1-844-363-4357.** In addition, our genetic counsellors proactively contact healthcare providers about abnormal results to provide clear next steps for their patients. Services are available from 8am-7pm EST in both English and French.

1. Dar et al. Am J Obstet Gynecol. Published online January 24, 2022. doi:10.1016/j.ajog.2022.01.019 | 2. Pergament et al. Obstet Gynecol. 2014 Aug; 124(2 Pt 1):210-8. | 3. Nicolaides et al. PrenatDiagn. 2013 Jun; 33(6):575-9. | 4. Ryan et al. Fetal Diagn Ther. 2016; 40(3):219-23 | 5. Dar et al. Am J Obstet Gynecol. Published online January 13, 2022. doi:10.1016/j.ajog.2022.01.002 | 6. Norton et al. Perinatal and genetic outcomes associated with no call cfDNA results in 18,497 pregnancies, SFMS's 40th Annual Pregnancy Meeting 2021. | 7.Norwitz et al. J Clin Med. 2019 Jun; 8:937 | 8. Hedriana et al. Prenat Diagn. 2020 Jan; 40(2):179-84. | 9. Nicolaides et al. Fetal Diagn Ther. 2014; 35(3):212-7. | 10. McKanna et al. Ultrasound Obstet Gynecol. 2019 Jan; 53(1):73-79 | 11. DiNonno.et al. J Clin Med. 2019 Aug; 8(9),1311. | 12. Internal data, Natera. | 13. Stokowski et al. Prenat Diagn. 2015 Dec; 35(12):1243-6. | 14. Jones et al. Ultrasound Obstet Gynecol. 2018 Feb; (2):275-6. | 15. Hooks et al. Prenat Diagn. 2014 May; 34(5):496-9. | 16. Schmid et al. Fetal Diagn Ther. 2018; 44(4):299-304. | 17. Palomaki et al. Genet Med. 2011 Nov; 13(11):913-20. | 18. Palomaki et al. Genet Med. 2012 Mar; 14(3):296-305. | 19. Porreco et al. Am J Obstet Gynecol. 2014 Oct; 211(4):365 e1-12. | 20. Mazloom et. al. Prenat Diagn. 2013 Jun; 3(6):591-7. | 21. Tynan et al. SMFM 37th Annual Pregnancy Meeting 2017 | 22. Sehnert et al. Clin Chem. 2011 Jun; 57(7):1042-9. | 23. Bianchi et al. Obstet Gynecol. 2012 May;119(5):890-901 | 24. Bianchi et al. N Engl J Med. 2014 Feb; 370(9):799-808 | 25. Verinata Health. Analytical validation of the Verifi prenatal test, 2012 | 26. The commercial protocol is not validated. Illumina marketing materials cite Srinivasan et al. Am J Hum Genet. 2013 Feb; 92(2):167-76, which does not match the number of reads used in commercial testing. | 27. Wald NJ, et al. First and second trimester antenatal screening for Down syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003; 10:56-104. | 28. Malone FD, et al. First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Downís syndrome. N Engl J Med. 2005; 353:2001-11. | 29. Wapner R, et al. First trimester screening for trisomies 21 and 18. N Engl J Med 2003; 349:1405-1413.

LifeLabsGenetics.com/Panorama

LifeLabs Genetics